Evidence map›Paper›PMID 41532364›Full record

ArticleInternal medicine journal2026

Recommendations for bone-directed therapy in patients with neuroendocrine tumour skeletal metastases at the New Zealand National Neuroendocrine Tumour Multidisciplinary Meeting.

Gayle Radley, Marianne S Elston, Ben Lawrence, Veronica Boyle

Abstract read
In one paragraph

Article in Internal medicine journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Gayle RadleyDepartment of Oncology, Te Toka Tumai Auckland, Auckland, New Zealand.
Marianne S ElstonWaikato Clinical Campus, University of Auckland, Hamilton, New Zealand.ORCID 0000-0002-0748-2300
Ben LawrenceDepartment of Oncology, Te Toka Tumai Auckland, Auckland, New Zealand.
Veronica BoyleDepartment of Oncology, Te Toka Tumai Auckland, Auckland, New Zealand.

Funding

Health Research Council of New Zealand 23-905
6 · The paper itself

Abstract

The role of anti-resorptive agents in patients with bone metastases from neuroendocrine neoplasms is unclear. Our aim was to review bone-specific treatment recommendations by the New Zealand National Neuroendocrine Tumour Multidisciplinary Meeting (MDM). Recommendations for bone-specific treatment were given at 29/365 MDMs (7.9%); 44.8% were confirmed to have received the recommended therapy. Bone-specific treatment recommendations were infrequent; there is a need for more data on the role of anti-resorptive agents in this group.

Indexed as

Bone Density Conservation AgentsBone NeoplasmsNeuroendocrine TumorsPractice Guidelines as TopicDiphosphonatesHumansNew ZealandBone Density Conservation AgentsDiphosphonatesbone neoplasmsdenosumabneuroendocrine neoplasmneuroendocrine tumoursradiotherapyspinal cord compressionzoledronic acid

Identifiers

PMID41532364
PMCPMC12978207

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.